Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S.3311 - American Made Pharmaceuticals Act of 2023
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Part D biosimilars utilization
Duration: September 4, 2015
to
December 31, 2017
General Issues: Health Issues , Government Issues , Veterans , Taxation/Internal Revenue Code , Budget/Appropriations , Copyright/Patent/Trademark , Pharmacy , Medicare/Medicaid
Spending: about $3,787,500 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Natl Security Council (NSC), Defense - Dept of (DOD), Executive Office of the President (EOP), Office of Science & Technology Policy (OSTP), Food & Drug Administration (FDA), Vice President of the U.S., Congressional Budget Office (CBO)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
David Sanders
Legislative Advisor, U.S. Patent and Trademark Office, U.S. Department of Commerce
Legislative Assistant, U.S. Representative Marsha Blackburn (R-TN)
Legislative and Press Intern, U.S. Senator Fred Thompson (R-TN)
U.S. Patent and Trademark Office
U.S. Representative Marsha Blackburn
U.S. Senator Fred Thompson
Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007)
Legislative Assistant, Representative Marsha Blackburn (2002-2004)
Legislative and Press Intern, Senator Fred Thompson (2000)
Ben Kenney
Director of Strategic Communications and Stakeholder Engagement, Centers for Medicare and Medicaid Services (2018-2021),
Associate Administrator, General Services Administration (2017-2018),
Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
Director of Strategic Communications and External Affairs, Centers for Medicare and Medicaid Services (2018-2021),
Associate Administrator, General Services Administration (2017-2018),
Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
Benjamin Kenney
CMS, HHS
Juliana Reed
n/a
Amanda Major
n/a
Ali McBride
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2024
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on June 26.
Original Filing: 301580461.xml
Lobbying Issues
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S.3311 - American Made Pharmaceuticals Act of 2023
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Part D biosimilars utilization
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
1st Quarter, 2024
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on April 22.
Original Filing: 301572623.xml
Lobbying Issues
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S.3311 - American Made Pharmaceuticals Act of 2023
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Part D biosimilars utilization
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
4th Quarter, 2023
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Jan. 17.
Original Filing: 301526850.xml
Lobbying Issues
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S.3311 - American Made Pharmaceuticals Act of 2023
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Part D biosimilars utilization
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
3rd Quarter, 2023
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301513478.xml
Lobbying Issues
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
2nd Quarter, 2023
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301484496.xml
Lobbying Issues
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Drug Rebate Reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
FDA foreign inspections
ASPR/BARDA funding and policy
Interchangeability of biosimilars legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
1st Quarter, 2023
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301456480.xml
Lobbying Issues
Drug Pricing Reform
Domestic Manufacturing
Medicare implications on biosimilars, Part D reform
Appropriations pertaining to American Made preference
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
Biosimilar Patient and Provider Education (including Part D)
FDA foreign inspections
ASPR/BARDA funding and policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
4th Quarter, 2022
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301433305.xml
Lobbying Issues
Drug Pricing Reform
Domestic Manufacturing
Medicare implications on biosimilars
Appropriations pertaining to FDA inspections and American Made preferences
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act, ASP+8
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
H.R. 7400 /S. 3991 American Made Pharmaceuticals Act
Biosimilar Patient and Provider Education (including Part D)
FDA foreign inspections
S. 3799 PREVENT Pandemics Act
ASPR/BARDA funding and policy
H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA)
H.R. 5376 Inflation Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP) Food & Drug Administration (FDA)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Drug Pricing Reform
Biosimilars Policy
BARDA funding
ASPR funding
ARPA-H funding and implementation
Industrial Supply and Financing
IRA implementation
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA)
3rd Quarter, 2022
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 18, 2022.
Original Filing: 301407897.xml
Lobbying Issues
Build Back Better Act
Drug Pricing Reform
ASP+8 for biosimilars
Domestic Manufacturing
Medicare implications on biosimilars
Appropriations pertaining to FDA inspections and American Made preferences
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
H.R. 7400 /S. 3991 American Made Pharmaceuticals Act
Biosimilar Patient and Provider Education (including Part D)
FDA foreign inspections
S. 3799 PREVENT Pandemics Act
ASPR/BARDA funding and policy
H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA)
H.R. 5376 Inflation Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR
ARPA-H
Industrial Supply and Financing
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP)
2nd Quarter, 2022
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on July 14, 2022.
Original Filing: 301380576.xml
Lobbying Issues
Build Back Better Act
Drug Pricing Reform
ASP+8 for biosimilars
Domestic Manufacturing
Medicare implications on biosimilars
Appropriations pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
American Made Pharmaceutical Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR
ARPA-H
Industrial Supply and Financing
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP)
1st Quarter, 2022
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on March 29, 2022.
Original Filing: 301343122.xml
Lobbying Issues
Build Back Better Act
Drug Pricing Reform
ASP+8 for biosimilars
Domestic Manufacturing
Medicare implications on biosimilars
Appropriations pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
American Made Pharmaceutical Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC) Defense - Dept of (DOD) Executive Office of the President (EOP) Office of Science & Technology Policy (OSTP)
Lobbying Issues
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR
ARPA-H
Industrial Supply and Financing
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP)
4th Quarter, 2021
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2022.
Original Filing: 301339157.xml
Lobbying Issues
Build Back Better Act
Drug Pricing
ASP+8 for biosimilars
Domestic Manufacturing
Medicare implications on biosimilars
Pass Through Status Extension
Appropriations and reach out pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
340B Drug Pricing Program
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC)
Lobbying Issues
Repeal of Most Favored Nations Rule
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
OPPS Pass-Through Status Extension
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR Funding
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2021.
Original Filing: 301315882.xml
Lobbying Issues
S.164 - Advancing Education on Biosimilars Act of 2021
Pass-Through Status Extension
Medicare payments for Biosimilars
Appropriations and reach out pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
340B Drug Pricing Program
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
340B Drug Pricing Program
HR 3683 Securing America's Pharmaceutical Supply Chain
S 2640 Disease X Act
S. 2662 Industrial Finance Corporation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC)
Lobbying Issues
Repeal of Most Favored Nations Rule
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
OPPS Pass-Through Status Extension
Drug Pricing Reform
Biosimilars Policy
BARDA
ASPR Funding
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2021
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Aug. 13, 2021.
Original Filing: 301294321.xml
Lobbying Issues
S.164 - Advancing Education on Biosimilars Act of 2021
Pass-Through Status Extension
Medicare payments for Biosimilars
Appropriations and reach out pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
340B Drug Pricing Program
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
H.R. 2815 - The BIOSIM Act
H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021
H.R. 2855 - Star Rating for Biosimilars
S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act
S. 1176 - Onshoring Essential Antibiotics Act
S. 1693 - Medical Supplies for Pandemics Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Natl Security Council (NSC)
Lobbying Issues
Repeal of Most Favored Nations Rule
Implementation of Buy American and Supply Chain Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
OPPS Pass-Through Status Extension
Agencies Lobbied
White House Office Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2021
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265345.xml
Lobbying Issues
S.164 - Advancing Education on Biosimilars Act of 2021
Pass-Through Status
Medicare payments for Biosimilars
Appropriations pertaining to FDA inspections
HHS Supply Chain Readiness
HHS Biosimilar Uptake
340B Drug Pricing Program
American-Made, Security of the American Pharmaceutical and Medical Supply Chain
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Vice President of the U.S. Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Repeal of Most Favored Nations Rule
Implementation of Buy American Executive Orders
American-Made Policies
American-Made Supply Chain
Security of the American Pharmaceutical and Medical Supply Chain
Agencies Lobbied
White House Office Vice President of the U.S. Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Jan. 4, 2021.
Original Filing: 301228501.xml
Lobbying Issues
Medicare related to biosimilars
H.R. 4455 - The BIOSIM Act Passed the House as part of H.R. 3.
Appropriations included in Committee report H.R. 2740; included also in FY 2021 Labor-H Committee report.
H.R. 6179/S. 4134 - Increasing Access to Biosimilars Act of 2020
H.R. 4597/S. 3466 - The ACCESS Act
H.R. 8624 - Protecting Access to Innovation during COVID-19 Act
S. 4295 Public Health Emergency Pass-Through Payment Fairness Act
Most Favored Nation Model for Medicare Part B Drugs and Biologicals Interim Final Rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Vice President of the U.S. Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues pertaining to pharmaceutical supply chain and manufacturing
Agencies Lobbied
White House Office Vice President of the U.S. Health & Human Services - Dept of (HHS)
3rd Quarter, 2020
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Nov. 4, 2020.
Original Filing: 301226035.xml
Lobbying Issues
Medicare related to biosimilars
H.R. 4455 - The BIOSIM Act Passed the House as part of H.R. 3.
Appropriations included in Committee report H.R. 2740; included also in FY 2021 Labor-H Committee report.
H.R. 6179/S. 4134 - Increasing Access to Biosimilars Act of 2020
H.R. 4597/S. 3466 - The ACCESS Act
H.R. 8624 - Protecting Access to Innovation during COVID-19 Act
S. 4295 Public Health Emergency Pass-Through Payment Fairness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Vice President of the U.S.
Lobbying Issues
Issues pertaining to pharmaceutical supply chain and manufacturing
Agencies Lobbied
White House Office Vice President of the U.S. Health & Human Services - Dept of (HHS)
3rd Quarter, 2020
Coherus Biosciences, Inc. filed a lobbying registration on Sept. 1, 2020 for in-house lobbying efforts, effective Aug. 1, 2020.
Original Filing: 301206103.xml
Issue(s) they said they’d lobby about: Biosimilars, Medicare Part B, Medicare Advantage, 340B Drug Pricing .
4th Quarter, 2017
Coherus Biosciences, Inc. in-house lobbying effort was terminated on Dec. 31, 2017
Original Filing: 300920903.xml
3rd Quarter, 2017
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 11, 2017.
Original Filing: 300902644.xml
Lobbying Issues
biosimilar reimbursement and support for market formation in the US
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Lobbying Issues
biosimilars reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Office of Management & Budget (OMB)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Biosimilars User Fee Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on July 12, 2017.
Original Filing: 300883833.xml
Lobbying Issues
biosimilar reimbursement and support for market formation in the US
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Lobbying Issues
biosimilars reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Office of Management & Budget (OMB)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Biosimilars User Fee Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on April 14, 2017.
Original Filing: 300865614.xml
Lobbying Issues
biosimilar reimbursement and support for market formation in the US
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
biosimilars reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Biosimilars User Fee Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Dec. 19, 2016.
Original Filing: 300842986.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Medicare Part D for biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
CMS Proposed Rule on PFS Part B with focus on biosimilars
Medicare Part D for biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Appropriations for biosimilars program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 17, 2016.
Original Filing: 300828704.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Medicare Part D for biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
CMS Proposed Rule on PFS Part B with focus on biosimilars
Medicare Part D for biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Congressional Budget Office (CBO)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Appropriations for biosimilars program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on July 14, 2016.
Original Filing: 300809869.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
CMS Proposed Rule on PFS Part B with focus on biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Congressional Budget Office (CBO)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA Appropriations for biosimilars program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on April 18, 2016.
Original Filing: 300793690.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
CMS Proposed Rule on PFS Part B with focus on biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Jan. 18, 2016.
Original Filing: 300774377.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
CMS Proposed Rule on PFS Part B with focus on biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
3rd Quarter, 2015
Coherus Biosciences, Inc. amended a lobbying report for in-house lobbying in Q32015 on Oct. 19, 2015
Original Filing: 300757209.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
3rd Quarter, 2015
In Q3, Coherus Biosciences, Inc. had in-house lobbyists. The report was filed on Oct. 16, 2015.
Original Filing: 300755554.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule (PFS) with a focus on provision for reimbursement of biosimilars
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate